[Form 4] Cardio Diagnostics Holdings Inc. Common stock Insider Trading Activity

Rhea-AI Filing Summary

Cardio Diagnostics Holdings Inc. (CDIO) – Form 4 insider filing

Director Peter K. Fung reported the grant of 1,736 stock options on 06/30/2025. Each option carries an exercise price of $3.60 and will expire on 06/30/2035. The filing indicates the transaction code “A,” denoting an acquisition rather than a sale. After this award, Fung directly holds 2,443 derivative securities (stock options) linked to CDIO common stock. No open-market purchases or disposals of common shares were disclosed.

Positive

• Director received 1,736 new stock options at an exercise price of $3.60, raising his derivative stake to 2,443 options

Negative

• None.

Insights

Financial Analyst

TL;DR – Routine option grant; modestly positive insider signal, immaterial to fundamentals.

The Form 4 shows a standard equity incentive: 1,736 options at $3.60 awarded to Director Peter K. Fung, increasing his direct derivative position to 2,443. Because this is a grant (code “A”) rather than an open-market purchase, cash outlay is zero and immediate balance-sheet impact negligible. Still, option grants slightly align director incentives with shareholders. No disposition of common shares suggests the director is not reducing exposure. Given the small size of the award and lack of cash transaction, the filing is not materially impactful to CDIO’s valuation but can be read as a neutral-to-positive governance signal.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fung Peter K

(Last) (First) (Middle)

C/O CARDIO DIAGNOSTICS HOLDINGS INC.

311 W. SUPERIOR ST. SUITE 444

(Street)

CHICAGO IL 60654

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cardio Diagnostics Holdings, Inc. [ CDIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$3.6	06/30/2025		A		1,736		06/30/2025	06/30/2035	Common Stock	1,736	$3.6	2,443	D

Explanation of Responses:

	/s/ Elisa Luqman as attorney-in-fact for Peter Fung	07/02/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CDIO director Peter K. Fung acquire according to the Form 4?

He received 1,736 stock options to buy CDIO common shares.

What is the exercise price and expiration date of the newly granted options?

The options are exercisable at $3.60 per share and expire on 06/30/2035.

How many derivative securities does Fung hold after this transaction?

He directly owns 2,443 stock options following the grant.

Were any common shares of Cardio Diagnostics bought or sold?

No. The filing reports only an option grant; no common stock transactions were disclosed.

When was the transaction and when was the Form 4 filed?

The transaction occurred on 06/30/2025, and the form was signed on 07/02/2024.